Experts have long known that weight loss has a positive effect on sleep apnea — but powerful new GLP-1 agonist medications are revealing just how dramatic that impact can be.
Patients with obstructive sleep apnea (OSA) taking tirzepatide (Mounjaro, Zepbound) who lost the most weight — more than 15% of their body weight — reduced by half the number of times their breathing stopped each hour during a sleep cycle. In many cases, OSA symptoms disappeared completely.
People Who Lost Weight Early Saw the Biggest Benefits — and Kept Them
In the study, people who lost the most weight in the first 20 weeks saw the greatest improvement in their sleep apnea symptoms. They were also more likely to stick with their weight loss efforts and ended up losing the most weight by the end of the year.
Obesity raises the risk of developing OSA because fat tissue around the neck and gut constricts the upper airway and lungs during sleep.
“Our results show the importance of early and intensive weight reduction for optimized improvements in patients with OSA and obesity,” Ying Ni Lin, MD, a sleep researcher at Shanghai Jiao Tong University School of Medicine in China, said at the World Sleep Conference 2025 in Singapore.
Researchers compared results from 469 patients, some on tirzepatide and others taking a placebo. Two trials examined different groups: patients using CPAP therapy and patients not using CPAP therapy. CPAP — continuous positive airway pressure — is a machine that pumps air into the windpipe, helping to keep it open during sleep. People taking the drug saw much larger improvements in their sleep apnea severity than did those given a placebo, regardless of whether they were using CPAP.
Cardiovascular Fall-On Effects
Patients who experienced the most weight loss also improved their cardiovascular health — reducing their blood pressure and lowering blood levels of C-reactive protein (which promotes inflammation and indicates an increased risk of atherosclerosis, or artery blockages).
Sleep apnea directly impacts cardiovascular risk — when you don’t get enough oxygen during sleep, it takes a toll on the heart and makes you more susceptible to heart attack and stroke.
Those with the most weight loss showed the most significant improvements in sleep apnea symptoms and cardiovascular health.
Weight Loss Drugs Also Prove This
You’re not alone. Aside from highlighting the ways in which weight loss affects health, GLP-1 agonists also reflect a big and welcome shift: Obesity is now recognized as a medical condition worthy of treatment, not a personal failing or matter of willpower.
If you’re living with sleep apnea and/or obesity, reach out for support. Talk to your doctor about your concerns and what options might fit your life and health goals. Together, you can explore choices (whether that includes medication or other interventions) and build a plan that meets your unique needs.
